If you have been reading about 三重激动剂 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-07. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Verification of research-grade material depends on documentation supplied with a sample. A certificate of analysis lists purity, identity, and the methods used to establish each value. Buyers comparing suppliers look at chromatographic purity figures, mass confirmation data, and whether methods are described in enough detail to be reproduced. Independent testing can confirm reported values but adds cost and time. Because the research chemical market is not uniformly regulated, provenance and documentation quality vary widely, and claims should be evaluated against raw data rather than summary labels.
Characterization of retatrutide in research settings relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase separation resolves the parent peptide from related impurities, while electrospray ionization mass spectrometry confirms molecular mass against a calculated value. Peptide mapping after enzymatic digestion can verify the amino acid sequence. Laboratories often combine orthogonal methods because no single technique establishes both identity and purity. Detected impurities typically include truncated sequences, oxidized residues, and deamidated forms that arise during synthesis or storage.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
Lyophilized material is generally held at minus 20 degrees Celsius or colder for long-term storage, protected from moisture and light. Solutions are handled under refrigeration, typically between 2 and 8 degrees Celsius, and used within a short window because degradation and microbial growth both accelerate in liquid. Repeated freeze-thaw cycles are avoided, and vials are equilibrated to room temperature before opening to reduce condensation. These are general laboratory conventions for peptides of this size rather than product-specific directions.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
== Mechanism of action == Apixaban is a highly selective, orally bioavailable, and reversible direct inhibitor of free and clot-bound factor Xa. Factor Xa catalyzes the conversion of prothrombin to thrombin, the final enzyme in the coagulation cascade that is responsible for fibrin clot formation. Apixaban has no direct effect on platelet aggregation, but by inhibiting factor Xa, it indirectly decreases clot formation induced by thrombin.
Even the Chilean and Río de la Plata governments mistrusted Bolívar, accusing him of not letting each people decide their future. Bolívar's attitude contributed to accentuate this negative climate. He was irritable and reacted violently to the slightest contradiction. His egomania, already great, increased in those days to unimaginable levels when he had territories from the Venezuelan Caribbean to the Bolivian altiplano under his control. According to a diplomatic source from the United States, in 1826, during the celebration of his birthday, Bolívar stated at a banquet in his honor that he was "the greatest man of all those recorded in history, and that not only the heroes of antiquity were inferior to him in liberal ideas, but also Washington and Napoleon had lagged behind." He also used to do various eccentricities, such as suddenly stopping on the table and kicking bottles and glasses, as if to indicate that he could do whatever he wanted in Peru. In addition, in 1828, when the Peruvians entered Bolivia and After Sucre was deposed, Bolívar sought to create a "Bogotá-Rio de Janeiro axis" abandoning his previous attempts to isolate the Brazilian monarchy to achieve an anti-Peruvian coalition. It was a failure due to Colombian political instability and the geographical distances between its centers of power.
Quality Management Development of new strategies for performance appraisal of hospital, out-patient clinics and laboratories. Development of quality-based documentation, database and communication systems or technical and administrative tools at TBRI. Development of quality-based safety systems for patients, personnel and utilized tools at TBRI, and upgrading of human capacity. In 2025, the Institute has over 3,000 researchers, mainly in the areas of cancer and infectious diseases.
Thioesters are common intermediates in many biosynthetic reactions, including the formation and degradation of fatty acids and mevalonate, precursor to steroids. Examples include malonyl-CoA, acetoacetyl-CoA, propionyl-CoA, cinnamoyl-CoA, and acyl carrier protein (ACP) thioesters. Acetogenesis proceeds via the formation of acetyl-CoA. The biosynthesis of lignin, which comprises a large fraction of the Earth's land biomass, proceeds via a thioester derivative of caffeic acid. These thioesters arise analogously to those prepared synthetically, the difference being that the dehydration agent is ATP. In addition, thioesters play an important role in the tagging of proteins with ubiquitin, which tags the protein for degradation. Oxidation of the sulfur atom in thioesters (thiolactones) is postulated in the bioactivation of the antithrombotic prodrugs ticlopidine, clopidogrel, and prasugrel.
=== Pseudoelasticity === Even though soft tissues have viscoelastic properties, i.e. stress as function of strain rate, it can be approximated by a hyperelastic model after precondition to a load pattern. After some cycles of loading and unloading the material, the mechanical response becomes independent of strain rate.
Sources: en.wikipedia.org
== Cause == Scurvy, including subclinical scurvy, is caused by a deficiency of dietary vitamin C since the human liver is unable to synthesize vitamin C. Provided the diet contains sufficient vitamin C, the lack of working L-gulonolactone oxidase (GULO) enzyme has no significance. In modern Western societies, scurvy is seldom present in average adults, although underfed people (drug users, the homeless, neglected children and geriatrics) are affected. Virtually all commercially available baby formulas contain added vitamin C, preventing infantile scurvy. Human breast milk contains sufficient vitamin C if the mother has an adequate intake. Commercial milk is pasteurized, a heating process that destroys the natural vitamin C content of the milk. Scurvy is one of the accompanying diseases of malnutrition (other such micronutrient deficiencies are beriberi and pellagra) and thus is still widespread in areas of the world dependent on external food aid. Although rare, there are also documented cases of scurvy due to poor dietary choices by people living in industrialized nations.
== History == The theory of electron capture was first discussed by Gian-Carlo Wick in a 1934 paper, and then developed by Hideki Yukawa and others. K-electron capture was first observed by Luis Alvarez, in vanadium, 48V, which he reported in 1937. Alvarez went on to study electron capture in gallium (67Ga) and other nuclides.
A drug carrier or drug vehicle is a substrate used in the process of drug delivery which serves to improve the selectivity, effectiveness, and/or safety of drug administration. Drug carriers are primarily used to control the release of drugs into systemic circulation. This can be accomplished either by slow release of a particular drug over a long period of time (typically diffusion) or by triggered release at the drug's target by some stimulus, such as changes in pH, application of heat, and activation by light. Drug carriers are also used to improve the pharmacokinetic properties, specifically the bioavailability, of many drugs with poor water solubility and/or membrane permeability. A wide variety of drug carrier systems have been developed and studied, each of which has unique advantages and disadvantages. Some of the more popular types of drug carriers include liposomes, polymeric micelles, microspheres, and nanoparticles. Different methods of attaching the drug to the carrier have been implemented, including adsorption, integration into the bulk structure, encapsulation, and covalent bonding. Different types of drug carrier utilize different methods of attachment, and some carriers can even implement a variety of attachment methods.
== Honors and recognition == Knudsen received the 2023 Paul Langerhans Medal by the German Diabetes Society for her work developing liraglutide. In October 2023, she received the STAT Biomedical Innovation award, and in 2024, she received the Mani L. Bhaumik Breakthrough of the Year Award. In 2024 she received the Lasker Award in clinical research. In 2024, Knudsen received the Golden Plate Award of the American Academy of Achievement, presented by Awards Council member Robert S. Langer. In 2025, Knudsen received the 2025 Breakthrough Prize in Life Sciences.
Sources: en.wikipedia.org
==== Resignation of Luis Barranzuela ==== Luis Barranzuela, the new Minister of the Interior, was a former police officer and the lawyer of Vladimir Cerrón until his appointment as minister. On 18 October 2021, Congress questioned the new minister over the 158 reprimands he got during his time as a police officer, and his ties to Free Peru. The parties Popular Action and Go on Country warned that they would not give confidence to the Vásquez cabinet if Luis Barranzuela wasn't removed from the cabinet. Despite pandemic restrictions established by the ministry he presided, Luis Barranzuela hosting a party for the Día de la Canción Criolla on 31 October 2021 at his home located in the district of Surco, in Lima. The party was attended by congressman Guillermo Bermejo, who upon being caught by the cameras of Latina Televisión fled the place in the van of his lawyer Ronald Atencio, who reportedly was another of the guests. Barrenzuela denied having a party and affirmed that it was only a work meeting, declaring that "Peru cannot stop". For his part, Bermejo declared that "the loud music was from an adjoining house". However, neighbors of Barranzuela declared to the local press that a party did take place, that it had started in the afternoon and that due to the discomfort of the loud music they decided to call the police. Interviewed by Perú21, a neighbor told that days before, cars on the streets around the minister's house had been removed, something unusual, which would suggest that the party had been planned.
Also in 2012, the group of Juho Rousu at University of Helsinki, Finland, introduced a machine learning method to predict molecular properties from tandem MS data. This concept was brought together with the fragmentation tree concept in 2015 resulting in CSI:FingerID, being introduced in SIRIUS 3. The fragmentation tree is used to predict a molecular fingerprint of the unknown molecule using machine learning, which in turn is used to search a molecular structure database such as PubChem. Molecular structure databases are orders of magnitude larger than reference spectra libraries (PubChem containing ~111 million compounds in 2021 compared to NIST Tandem Mass Spectral Library containing ~50.000 compounds in 2023). This kind of structure identification refers to the identity and connectivity (with bond multiplicities) of the atoms, but not stereochemistry information. Elucidation of stereochemistry is currently beyond the power of automated search engines. SIRIUS 3 also introduced the graphical user interface (GUI). In 2020, in cooperation with the group of Pieter C Dorrestein at UC San Diego, USA, molecular formula identification was improved based on derivative networks from complete biological datasets to rank molecular formula candidates. This method is called ZODIAC and has been integrated into SIRIUS 4. Also in 2020, in cooperation with Rousu's and Dorrestein's groups, CANOPUS for systematic compound class annotation was introduced to SIRIUS 4.
Centre of Policy and Legal Reform (CPLR), a non-governmental think tank founded in 1996. Center for Policy Studies in Ukraine, a non-governmental think tank founded in 1994. International Centre for Policy Studies, a non-governmental think tank founded in 1994. Razumkov Centre, a non-governmental think tank founded in 1994. It carries out research of public policy in the following spheres: domestic policy; state administration; economic policy; energy; land relations; foreign policy; social policy; international and regional security; national security and defense. Transatlantic Dialogue Center, a non-governmental think tank founded in 2021.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
Purity is usually reported from reversed-phase high-performance liquid chromatography with ultraviolet detection. Peak area percentage gives a purity figure, though it does not prove identity. Mass spectrometry is used alongside chromatography to confirm the expected molecular mass.